For instance, an embryonic MV (MV-CEA) expressing recombinant carcinoembryonic antigen (CEA) and an oncolytic MV (MV-NIS) encoding a thyroid sodium-iodine cotransporter were employed in a clinical trial for ovarian and peritoneal carcinoma (NCT00408590). Here, CEACAM5 is linked to peritoneal carcinoma.